Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare Inc (SRTS) delivers innovative superficial radiation therapy solutions for non-melanoma skin cancers and keloid treatment. This news hub provides investors and medical professionals with essential updates on the company's FDA-cleared devices, clinical advancements, and strategic partnerships.
Access timely updates on treatment protocol developments, technology enhancements, and market expansion initiatives. Our curated news collection features regulatory milestones, peer-reviewed study results, and operational updates directly impacting the dermatology and radiation oncology sectors.
Key focus areas include new device clearances, clinical efficacy data, partnership announcements with healthcare providers, and innovations in non-invasive treatment delivery. All content undergoes rigorous verification to ensure accuracy in reporting medical device developments.
Bookmark this page for consolidated access to SRTS's latest advancements in targeted radiation therapy. Return regularly for verified updates on this pioneering medical technology company's progress in transforming skin condition treatment protocols.
Sensus Healthcare reported an 83% revenue increase year-over-year, achieving $3.1 million in the first quarter of 2021 compared to $1.7 million in 2020. The company installed its 500th unit and narrowed its net loss to $1.1 million or $0.07 per share, down from $3.6 million or $0.22 per share last year. Gross profit rose to $1.6 million, with a gross margin of 51.6%. Cash and equivalents totaled $13.7 million as of March 31, 2021. Management anticipates continued revenue growth driven by higher reimbursement rates and expanding market acceptance.
Sensus Healthcare, Inc. (Nasdaq: SRTS) will host a conference call on May 6, 2021, at 4:30 p.m. Eastern Time to discuss its Q1 2021 financial results and provide a business update. The call will be accessible via dial-in numbers (888-390-3967 for U.S. and Canada; 862-298-0702 for international) and a live webcast. Sensus Healthcare specializes in non-invasive medical devices for oncological and non-oncological conditions, including the Sculptura™ system and SRT-100™ technology for skin cancer treatments, emphasizing innovation in patient care.
Sensus Healthcare (Nasdaq: SRTS) announced a significant milestone as its SRT-100™ system successfully treated its first canine patient, Daisy, at Colorado State University's Flint Animal Cancer Center. Daisy had two mast cell tumors that were reduced after six treatments, avoiding surgery. This landmark event highlights Sensus's innovations in superficial radiation therapy (SRT), expanding the potential use of their technology in veterinary medicine. The partnership aims to develop treatment protocols and publish clinical data, promoting the commercial viability of SRT-100 in a new market.
Sensus Healthcare, Inc. (NASDAQ: SRTS), a leader in innovative medical devices, announced participation in three virtual investment conferences in March 2021. Key events include the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, the Roth Conference featuring a live panel on March 16, and the Maxim Group Emerging Growth Conference on March 17-18. These conferences offer opportunities for one-on-one meetings with institutional investors. Sensus specializes in non-invasive treatments for oncological and non-oncological conditions, enhancing patient care globally.
Sensus Healthcare (SRTS) reported a fourth-quarter net income of $1.0 million on revenues of $5.1 million, down from $8.5 million in Q4 2019. Despite shipping 18 systems, including sales in China, the revenue drop is attributed to COVID-19 impacts. The company achieved a 63.4% gross profit margin. Major highlights include increased Medicare reimbursement rates and promising clinical studies on superficial radiation therapy (SRT) for keloid treatment. The company's cash reserves stood at $14.9 million as of December 31, 2020, with a focus on recovery in the upcoming year.
Sensus Healthcare has received U.S. Patent No. 10,607,802 B2 for its Sculptura™ radiation therapy technology, enhancing treatment for all solid tumors. This patent covers the innovative beam splitting and sculpting capabilities, which are crucial for targeted therapies. The company has now secured five patents since early 2020. CEO Joe Sardano emphasized the potential for licensing this technology beyond Sculptura. The firm specializes in non-invasive treatment options and is dedicated to improving cancer care and patient quality of life.
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on February 25, 2021, at 4:30 p.m. ET to discuss its Q4 2020 financial results and provide a business update on recent and upcoming milestones. The call can be accessed via dial-in numbers and will also be available as a live webcast. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions, including its Sculptura™ system for cancer therapy and SRT-100™ for non-melanoma skin cancers.
Sensus Healthcare (Nasdaq: SRTS) announced that Holy Name Medical Center in New Jersey has acquired its low-dose radiation therapy system to treat pneumonia in COVID-19 patients. This portable solution allows for bedside treatment, minimizing potential exposure for patients. Preliminary data suggest a positive therapeutic effect on COVID pneumonia. CEO Joe Sardano expressed optimism about the partnership, emphasizing Holy Name's success with investigational therapies. Sensus's technology, including the SRT-100+™ and SRT-100 Vision™, offers a promising new tool during the pandemic.
Sensus Healthcare (Nasdaq: SRTS) has entered an exclusive distribution agreement with Ekpac Healthcare Ltd. for the SRT-100™ systems in China and Hong Kong, effective January 1, 2021. This agreement aims to enhance the delivery of non-invasive treatment for non-melanoma skin cancer and keloids. With 40 units currently installed across various medical facilities, Sensus anticipates significant growth in unit installations in the region. Ekpac Healthcare brings over a century of experience in the market and will leverage its distribution network to achieve sales success for these advanced medical devices.
Sensus Healthcare announces a significant change in reimbursement for Radiation Treatment Delivery code 77401, set to increase by 66% to approximately $41 per treatment, effective January 1, 2021. This increase is the first major adjustment since 2002. In addition, related Evaluation & Management codes will also see double-digit percentage increases. This development follows a concerted effort by Sensus and healthcare advocates to secure fairer payments for Superficial Radiation Therapy (SRT), a non-invasive treatment for skin cancer.
